Pfizer Inc. (PFE)

These high-quality companies have strong balance sheets and operate in high-demand markets poised to do well through any economic crisis.

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Let's look at the stocks that will get crushed and that you can't touch right now.

I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.

There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.

PFE's charts are constructive and traders could go long at current levels.

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.

Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.

After a strong day for fixed-income markets, let's learn from 2008 how to play this volatility.

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

When the central bank is on top of their game as they have been of late, credit must go where credit is due.

The daily trading volume has increased over the past two months telling us that PFE is not falling of its own weight but rather investors are voting with their feet.

But don't throw up your arms yet -- here are names that could be golden opportunities.

Here's how we would play shares of the pharmaceutical giant now.

These Dow stocks all yield above 3.3% right now, but are they worth the risk?

This coronavirus remains a China-centric problem? People are not yet dying in other countries. Do we have to worry here? That's the wrong question.

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Also: People's Bank of China, the Fed, U.S./China trade deal, Brexit, USMCA.

The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.

These stocks are priced for total imperfection. That's just what you want.

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.